CVS Health (NYSE:CVS – Free Report) had its target price decreased by Mizuho from $73.00 to $66.00 in a research note issued to investors on Thursday, Benzinga reports. Mizuho currently has an outperform rating on the pharmacy operator’s stock.
CVS has been the subject of a number of other reports. Truist Financial increased their price target on CVS Health from $66.00 to $76.00 and gave the company a “buy” rating in a research note on Friday, October 11th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $62.00 target price on shares of CVS Health in a report on Tuesday, October 1st. Evercore ISI upped their price target on shares of CVS Health from $62.00 to $75.00 and gave the company an “outperform” rating in a report on Tuesday, October 8th. Deutsche Bank Aktiengesellschaft dropped their target price on shares of CVS Health from $64.00 to $63.00 and set a “hold” rating on the stock in a report on Friday, August 9th. Finally, TD Cowen upgraded shares of CVS Health from a “hold” rating to a “buy” rating and lifted their price target for the stock from $59.00 to $85.00 in a research report on Friday, October 4th. Nine equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $74.58.
Check Out Our Latest Report on CVS Health
CVS Health Trading Up 0.7 %
CVS Health (NYSE:CVS – Get Free Report) last released its earnings results on Wednesday, August 7th. The pharmacy operator reported $1.83 EPS for the quarter, beating the consensus estimate of $1.73 by $0.10. The firm had revenue of $91.23 billion for the quarter, compared to analysts’ expectations of $91.41 billion. CVS Health had a net margin of 1.98% and a return on equity of 12.72%. CVS Health’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter last year, the company earned $2.21 EPS. Equities analysts predict that CVS Health will post 6.41 earnings per share for the current year.
CVS Health Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Friday, November 1st. Stockholders of record on Monday, October 21st will be given a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.71%. The ex-dividend date of this dividend is Monday, October 21st. CVS Health’s dividend payout ratio (DPR) is 46.75%.
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in CVS. Livelsberger Financial Advisory purchased a new position in shares of CVS Health during the 3rd quarter valued at $31,000. Crewe Advisors LLC purchased a new position in CVS Health in the first quarter valued at about $40,000. Retirement Group LLC increased its position in CVS Health by 54.3% in the 1st quarter. Retirement Group LLC now owns 517 shares of the pharmacy operator’s stock worth $41,000 after purchasing an additional 182 shares during the last quarter. Kathleen S. Wright Associates Inc. purchased a new stake in shares of CVS Health during the 3rd quarter worth about $33,000. Finally, First Community Trust NA grew its stake in shares of CVS Health by 116.2% in the 2nd quarter. First Community Trust NA now owns 562 shares of the pharmacy operator’s stock valued at $33,000 after buying an additional 302 shares in the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.
CVS Health Company Profile
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
Featured Stories
- Five stocks we like better than CVS Health
- 3 Warren Buffett Stocks to Buy Now
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- The Significance of Brokerage Rankings in Stock Selection
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Find and Profitably Trade Stocks at 52-Week Lows
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.